JPRN-UMIN000000914CompletedPhase 1
Dendritic cell-based tumor-specific immunotherapy against malignant brain tumor - Phase I clinical trial - Immunotherapy against malignant brain tumor
Conditions
Trial Snapshot
- Phase
- Phase 1
- Status
- Completed
- Sponsor
- Shizuoka Cancer Center
- Enrollment
- 12
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Ages
- 20years-old to 80years-old (—)
- Sex
- All
Inclusion Criteria
- Not provided
Exclusion Criteria
- •1. Within 28 days after the last treatment against cancer 2. Severe systemic infection, hematostatic dysfunction, and organ disorder 3. Steroid treatment, except used for cerebral decompression 4. Hypersensitivity to DC vaccine 5. Severe immunological disorders (autoimmune disease, immunosuppression) 6. Multiple cancers 7. Anaphylaxis to synthetic peptides
Investigators
Similar Trials
Completed
Phase 2
Dendritic cell-based immunotherapy against metastatic melanoma patientsmetastatic melanomaJPRN-UMIN000006849Shizuoka Cancer Center24
Completed
Phase 2
Activated dendritic cell-based tumor-specific immunotherapy against high grade glioma-Phase II trialHigh-grade gliomaJPRN-UMIN000011474Shizuoka Cancer Center34
Unknown
Phase 1
Dendritic cell therapy and intratumor dendritic cell injection therapy using Tumor associated antigen or tumor lysate for patients with advanced and recurrent canceradvanced and recurrent cancerJPRN-UMIN000000775Fukushima Medical University25
Completed
Phase 2
Dendritic Cell Vaccine for the treatment of Stage IIIb Cervical Cancer patientsCTRI/2016/12/007530Department of Science and Technology DST54
Not yet recruiting
Not Applicable
Dendritic cell-based immunotherapy combined with low-dose cyclophosphamide in patients with malignant pleural mesotheliomamesothelioma10035597NL-OMON32554Erasmus MC, Universitair Medisch Centrum Rotterdam10